Cognitive Biases in Strategy and Execution
Listen now
Description
In this episode, Stacey is joined by Alex Castro to talk about accepting that bias does exist, and strategies for managing and moving beyond biased decision-making practices. Biases is a very interesting topic, and one that we take very seriously in life science manufacturing, as it can impact the quality of the product and add undue risk in this highly regulated environment. Interestingly, many do not consider their personal biases and their impacts on our decision-making and general ways of thinking. About Our Guest: Alex Castro Alex Castro is an aligner of execution to strategy for digital transformation & innovation, best-selling author, and creator/founder of ReM Score™. Alex believes that the gap between ideas (strategy) and execution is a persistent problem that is sidelining too many high-potential digital transformation and innovation growth opportunities. What will set companies apart in these uncertain economic times are those that reduce the falloff rate of good ideas during execution, seeing more of them create value, resulting in ultimately thriving in the ‘next normal.’ Aligning execution to your ideas for digital transformation and innovation is rooted in removing the biases that have us repeating the same errors in estimating our capabilities to execute. There is a way to calculate your execution capability for each idea you have, so more of them come to life, and you and your company win more. Alex is a charismatic, intelligent, and knowledgeable guest, with plenty of wisdom to share.   Voices in Validation brings you the best in validation and compliance topics. Voices in Validation is brought to you by IVT Network, your expert source for life science regulatory knowledge. For more information on IVT Network, check out their website at http://ivtnetwork.com.
More Episodes
The pharmaceutical quality control laboratory serves one of the most important functions in pharmaceutical production and control. Poor laboratory practice may yield compliance issues, higher costs, increased cycle time, and delayed product introductions. Avoiding all that means consistent lab...
Published 04/05/22
Published 04/05/22
The much-discussed revision to the EU GMP Annex 1 is expected to be published early this year, bringing some major changes to drug developers’ current process and manufacturing methods for sterile products. Although the draft revision has been widely shared and commented on, it is still unclear...
Published 03/29/22